Mersana Therapeutics Statistics
Total Valuation
MRSN has a market cap or net worth of $227.59 million. The enterprise value is $77.52 million.
| Market Cap | 227.59M |
| Enterprise Value | 77.52M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MRSN has 122.36 million shares outstanding. The number of shares has increased by 12.94% in one year.
| Shares Outstanding | 122.36M |
| Shares Change (YoY) | +12.94% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 99.48% |
| Float | 75.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.94 |
| Forward PS | n/a |
| PB Ratio | 8.13 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.51, with a Debt / Equity ratio of 1.18.
| Current Ratio | 3.51 |
| Quick Ratio | n/a |
| Debt / Equity | 1.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.95 |
Financial Efficiency
Return on equity (ROE) is -260.70% and return on invested capital (ROIC) is -233.98%.
| Return on Equity (ROE) | -260.70% |
| Return on Assets (ROA) | -54.00% |
| Return on Capital (ROIC) | -233.98% |
| Revenue Per Employee | $311,366 |
| Profits Per Employee | -$1.10M |
| Employee Count | 123 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.61% in the last 52 weeks. The beta is 1.49, so MRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -45.61% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 2.72 |
| Relative Strength Index (RSI) | 29.52 |
| Average Volume (20 Days) | 1,505,136 |
Short Selling Information
The latest short interest is 10.45 million, so 8.54% of the outstanding shares have been sold short.
| Short Interest | 10.45M |
| Short Previous Month | 11.06M |
| Short % of Shares Out | 8.54% |
| Short % of Float | 13.89% |
| Short Ratio (days to cover) | 6.38 |
Income Statement
In the last 12 months, MRSN had revenue of $38.30 million and -$134.81 million in losses. Loss per share was -$1.13.
| Revenue | 38.30M |
| Gross Profit | 38.30M |
| Operating Income | -142.87M |
| Pretax Income | -134.81M |
| Net Income | -134.81M |
| EBITDA | -125.58M |
| EBIT | -130.72M |
| Loss Per Share | -$1.13 |
Balance Sheet
The company has $183.15 million in cash and $33.08 million in debt, giving a net cash position of $150.07 million or $1.23 per share.
| Cash & Cash Equivalents | 183.15M |
| Total Debt | 33.08M |
| Net Cash | 150.07M |
| Net Cash Per Share | $1.23 |
| Equity (Book Value) | 27.99M |
| Book Value Per Share | 0.23 |
| Working Capital | 134.13M |
Cash Flow
In the last 12 months, operating cash flow was -$172.53 million and capital expenditures -$1.39 million, giving a free cash flow of -$173.92 million.
| Operating Cash Flow | -172.53M |
| Capital Expenditures | -1.39M |
| Free Cash Flow | -173.92M |
| FCF Per Share | -$1.43 |
Margins
Gross margin is 100.00%, with operating and profit margins of -373.05% and -352.01%.
| Gross Margin | 100.00% |
| Operating Margin | -373.05% |
| Pretax Margin | -352.01% |
| Profit Margin | -352.01% |
| EBITDA Margin | -327.89% |
| EBIT Margin | -341.33% |
| FCF Margin | -454.13% |
Dividends & Yields
MRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.94% |
| Shareholder Yield | -12.94% |
| Earnings Yield | -59.23% |
| FCF Yield | -76.42% |
Analyst Forecast
The average price target for MRSN is $5.57, which is 199.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.57 |
| Price Target Difference | 199.46% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 50.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MRSN has an Altman Z-Score of -6.34 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.34 |
| Piotroski F-Score | 3 |